Journal of Crohns & Colitis

Article	Citations
P1104 Shifting Surgical Landscape in Crohn's Colitis: Laparoscopic Supremacy and Robotic Upsurge	584
P171 PSC/IBD and IBD have similar type and location of colonic lesions, but Dye ChromoEndoscopy (DCE) increases detection rate compared to White Light Endoscopy (WLE)	156
P601 Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational R	146
P301 Relapse rates after withdrawal of thiopurines in patients with Inflammatory Bowel Disease	144
P132 An audit of quality of histopathology reporting of colorectal mucosal biopsies for the diagnosis and assessment of Inflammatory Bowel Disease	116
DOP26 The relationship between vedolizumab therapeutic drug monitoring, biomarkers of inflammation, and clinical outcomes in Inflammatory Bowel Disease in the real-world setting	103
P355 Preferences and satisfaction of IBD patients in whom the adalimumab regimen was changed from 40 mg weekly to 80 mg every other week: the ADASCAL study	100
P663 Long-term follow up in IBD: 10-year observational study of a UK IBD cohort	85
P162 The Biosimilar Switch: IBD nurse's experience in Our Lady of Lourdes Hospital	84
P367 Are patients with Inflammatory Bowel Disease and two or more associated Immune-Mediated Inflammatory Diseases different from those with no or one associated disease?	76
P497 Malnutrition in inflammatory bowel disease: a correlation between clinical and nutritional parameters	75
P273 Defining the prognosis of children with Crohn Disease with the support of magnetic resonance enterography: a multi-center multi-reader study	75
P1090 Exposure to an inflammatory prenatal environment and the risk of Inflammatory Bowel Disease in the offspring: a population-based cohort study	70
P081 The integration of transcriptomic and microbiomic data links several intestinal bacterial families with key biological functions in the development of postoperative recurrence in Crohn's disease	60
DOP69 Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker study	58
P837 Improving Vaccination Rates in Patients with Inflammatory Bowel Disease: A Single Centre Audit and Quality Improvement Project	58
P926 Improved standards of colonoscopy for Inflammatory Bowel Disease through implementation of key performance measures - A quality improvement initiative	57
P607 Increased rates of fractures and malignancy in elderly onset IBD in Singapore	56
P051 IFNγ-macrophages could mediate EMT in Crohn’s disease through the WNT pathway	50
P513 Treatment persistence in bio-naive patients with long-standing Crohn’s disease treated with first-line biologics: real-life data from a Croatian tertiary center	49
P408 Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance	47
P059 GB004 drives protective effects on immune cells and epithelial cells using human ex vivo monolayer and co-culture systems	47
P269 Spaciotemporal machine learning analysis of complete small bowel capsule endoscopy videos for prediction of outcomes in Crohn’s disease	45
P440 First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)	44
OP14 Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencing	44

P719 Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infection	43
P360 Aggressive Inflammatory Bowel Disease is associated to Hermansky-Pudlak Syndrome: Characterization of a Puerto Rican Cohort	43
P454 Evaluation of the nutritional care status in italian centers managing patients affected by inflammatory bowel disease	41
P297 Treatment of patients with complex perianal Crohn’s disease with darvadstrocel: a single-institution real life experience	41
P352 Occurrence of moderate to severe anaemia and utilization and efficacy of intravenous iron therapies in a nationwide cohort of Inflammatory Bowel Disease patients	41
P368 Safety issues of azathioprine in patients with inflammatory bowel disease: clinical experience from a referral center	40
DOP16 The ratio of submucosa thickness to the total bowel wall thickness can be a sonographic parameter to estimate endoscopic remission in Ulcerative Colitis	38
P570 Prevalence and risk factors for intestinal resection in patients with Crohn’s disease in a Greek referral center	38
P732 Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results	37
P365 Incidental terminal ileitis in asymptomatic patients. Is it Crohn’s disease?	37
P060 Increased metabolic activity of faecal Sutterella Wadsworthensis at IBD onset is associated with an increased risk of escalation to biologic therapies - Results from the Birimingham Inception Coh	36
P024 Synergistic effect of phytochemicals combination including ginsenosides and curcumin on recovery from radiation-induced toxicity	35
P929 Relation between Crohn’s disease phenotype and response to ustekinumab in Stockholm – the STOCUSTE study	34
P996 Clinical Efficacy and Predictive Factors for the Effectiveness of Granulocyte and Monocyte Adsorption Apheresis Therapy for Ulcerative Colitis：A Retrospective Observational Single Center Study	34
P143 Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitis	34
ECCO Grant Untangling the gut phagosome dynamics of the relapse/remission cycle in ulcerative colitis	33
P694 Age is a strong of predictive risk factor for anti-TNF therapy related adverse events in IBD patients	33
P899 Inflammatory Bowel Disease Patients Show More Recognizable Digestive Symptoms of COVID-19: A Questionnaire Study	33
P514 Beyond the First Attempt: A Multi-Centre UK Analysis of Second JAK Inhibitor Use in Ulcerative Colitis	33
P228 Predictors of steroid therapy refractoriness in admitted Acute Severe Ulcerative Colitis patients	32
DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort	32
P747 Assessment of a microlearning programme for patients with Inflammatory Bowel Disease (The ADEII project) on ansiety/depression status and illness perception	32
P918 Can we rely on HLA to predict resistance to biological therapy in Inflammatory Bowel Disease patients?	31
P771 Comparing obstructive symptoms and dietary restrictions with Crohn's disease stricture severity	30
P554 Does vitamin D level correlates with disease activity in inflammatory bowel disease patients?	30
P387 Short and long-term outcomes of surgery for inflammatory (uncomplicated) ileocecal Crohn’s disease: multicentric retrospective analysis of 211 patients	30
DOP56 Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease	30
P250 Geriatric impairments associate with mortality and hospitalisations during follow-up in older IBD outpatients	30
P906 The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease. A retrospective observational study	30
P708 Ileal involvement defined by Montreal classification in Crohn’s disease is associated with a distinct microbial composition in ileal and colonic mucosa	30
P617 Trends in Pediatric Inflammatory Bowel Disease-attributable direct costs: A Canadian population-based analysis	29
P007 ORMDL proteins shape homeostasis in the intestinal epithelium by regulating endoplasmic reticulum architecture and autophagy	29
P187 Major Depression in patients with Ulcerative Colitis and its relationship with clinical activity	29
P456 Ig glycosylation in ulcerative colitis: it’s time for new biomarkers	29
P664 Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)	29
P360 Prevalence and risk factors for fatigue in patients with inflammatory bowel disease and endoscopic healing	28
P277 Assessment of fatigue as a patient-reported outcome: Correlation with baseline disease activity and therapy response in Inflammatory Bowel Disease	28
P616 Safety of COVID-19 vaccines in patients with IBD	28
P177 Adherence to a bowel cleansing regimen for pan-enteric capsule endoscopy in patients with suspected Crohn’s disease and factors affecting the image quality	28
P1079 Mindfulness-based cognitive therapy to reduce psychological distress in patients with Inflammatory Bowel Disease: first results of a multicentre randomised controlled trial (MindIBD)	28
DOP88 Long-term real-world data of ustekinumab in Crohn’s Disease – the Stockholm ustekinumab study – STOCUSTE	28
P672 A tertiary multicenter cohort of patients with chronic intestinal pseudo-obstruction and Crohn’s disease: a rare association with a high prevalence of monogenic disorders	28
Corrigendum to: ECCO CONFER Investigators, Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series	28
Corrigendum to: Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases	28
P674 Predictors of response to biologics in Crohn’s Diseases: A population-based study from the epi-IIRN	28
P750 Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel Disease	27
P222 Chronic pain is common in Paediatric Inflammatory Bowel Disease and impacts quality of life	27
P139 Inflammatory bowel disease and impairment of working life	27
OP32 The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo	27
P127 Inflammatory Bowel Disease-associated colorectal cancers: retrospective cohort study from a tertiary centre surveillance programme over 10 years	26

P833 Cervical cancer risk in newly diagnosed ulcerative colitis: a nationwide population-based study	26
P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry	26
P709 Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn’s disease of the small intestine	26
P501 Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort	26
P113 Protein fingerprint biomarkers of collagen remodeling can evaluate fibrogenesis in an in vitro colonic scar-in-a-jar model	25
P149 Novel capillary blood point-of-care test for adalimumab and infliximab trough levels: Effects of abnormal blood conditions on the test result	25
P083 JAK/STAT pathway and IL-6 activity in moderate to severe Ulcerative Colitis	25
P310 Smoking is not an independent risk factor for surgery in patients with Crohn’s Disease on biologic therapy	25
P294 Assessment of Fatigue and Associated Factors in Patients with Inflammatory Bowel Disease: A Questionnaire-based Study	25
P483 Patient-reported quality of life, anxiety, and depression associated with switching originator infliximab to biosimilar	24
OP05 Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study	24
P358 Long-term clinical outcomes of intestinal Behçet’s disease: a 30-year cohort study at a tertiary hospital in South Korea	24
P130 Comparison of the clinical course of Ulcerative Colitis according to the presence or absence of clinical symptoms at the time of diagnosis	24
P324 Long-term impact of the COVID-19 pandemic on Inflammatory Bowel Disease healthcare utilization: A two-year nationwide update	24
P089 Colonic explant lactate concentration and inflammatory protein secretion in ulcerative colitis	24
P308 A new endoscopic scoring system corresponding to histological healing using linked color imaging in ulcerative colitis: SOUL study	24
P0279 Assessing patient-reported health status in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Results from the communicating needs and features of IBD experiences (CONFIDE) survey	23
P473 Real world experience with the Crohn’s Disease Exclusion Diet (CDED) in a tertiary IBD clinic	23
P212 The Impact of Crohn’s Disease in Patients with Colorectal Cancer: A Danish Nationwide Cohort Study, 2009-2019	23
P1213 The role of stress in dietary choices and disease outcomes in Inflammatory Bowel Disease	23
DOP115 Exophiala dermatitidis aggravates colitis through the Syk-CARD9 signaling pathway	23
Video Capsule Endoscopy can Identify Occult Luminal Crohn’s Disease in Patients with Isolated Perianal Fistulas	23
Diagnosis and Outcome of Extranodal Primary Intestinal Lymphoma in Inflammatory Bowel Disease: An ECCO CONFER Case Series	23
P0435 Comparative analysis between capsule endoscopy and ileocolonoscopy for activity detection in ileal Crohn’s disease. Preliminary results from the CAPITER study, a multicenter study from the Young	23
P1144 Forecasting the Future Prevalence of Inflammatory Bowel Disease in Korea through 2048: An Epidemiologic Study Employing Autoregressive Integrated Moving Average Models	23
P0742 Real-world efficacy and safety of Upadacitinib in IBD patients. Preliminary data from the Apulian Network for Inflammatory Bowel Disease (AN-IBD)	23
DOP053 Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA)	23
P1288 The Association of Long-term Night Shift Work and Related Circulating Proteins with Inflammatory Bowel Disease: A Prospective Cohort and Multi-omics Study	22
P1244 Differential impact of appendectomy with appendiceal inflammation versus no inflammation on inflammatory bowel disease risk in a population-based cohort	22
P0003 Differential Effects of JAK Inhibitors on Epithelial-Immune Interaction in Inflammatory Bowel Disease	22
P0406 Complications after ileal pouch-anal anastomosis in patients with Ulcerative Colitis and primary sclerosing cholangitis	21
DOP022 Shared and Distinct Features of the Gut Microbiome in Immune-mediated Inflammatory Diseases: Initial Analysis from the INTEGRATE Cohort Study	21
P1252 Prevalence, Incidence and Mortality of Pediatric Inflammatory Bowel Disease in Catalonia	21
P0166 Changes in bone mineral density in young patients with inflammatory bowel diseases	21
P0089 Infra-red microspectroscopy provides quantitative assessment of fibro-inflammation in Crohn’s disease strictures and predicts post-operative recurrence	21
P0391 The impact of point of care ultrasound on time to initiating advanced therapy in IBD (GUIDE-IBD): A randomised controlled trial	21
DOP016 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension	21
DOP012 Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical study	20
DOP057 Early serum and faecal cytokines predict clinical outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC	20
P0483 Assessment of Disease Activity in Pediatric Inflammatory Bowel Disease Using Intestinal Ultrasound: A Comparative Diagnostic Analysis	20
P0453 Intestinal Ultrasound Correlates with Patient-Reported IBD Disability in Ulcerative Colitis: A Step Towards Integrated Monitoring	20
P0381 Correlation Between Rectal Endoscopic and Histological Involvement and the Prevalence and Severity of Ano-Perineal Lesions in Inflammatory Bowel Disease	20
P0250 Circulating blood matrix metalloproteinase (MMP)-10 and 12 can accurately predict mucosal healing in Inflammatory Bowel Disease (IBD) in a multi-centred prospective longitudinal cohort study (20	20
DOP026 Porphyromonas gingivalis secreted htpG disrupts TLR4/ PAPSS2-mediated mucin sulfation and aggravates ulcerative colitis	20
P0346 Pouch Fistulas: Experience From a Tertiary Center	20
P0292 CD8+ Cell Dominance in Immune Checkpoint Inhibitor-Induced Colitis and Its Heterogeneity Across Endoscopic Features	20
P0551 Diagnostic Accuracy of Low-Cost Blood Test Inflammatory Markers in Severe Ulcerative Colitis	19
P0893 Angiopoietin-like Protein 8 (ANGPTL8) in Inflammatory Bowel Disease and Its Response to Anti-TNFα Therapy; A Prospective Multi Center Study	19
P675 Flavonoid-degrading bacteria have central positions in correlation network analysis in patients with Inflammatory Bowel Disease	19
P0818 Addressing unmet needs in adult Inflammatory Bowel Disease care	19
P0746 Impact of timing of prophylaxis therapy on post-operative endoscopic recurrence in a real-life cohort of patients whit Crohn’s disease	19
P748 Pharmacokinetics, relative bioavailability, and dose proportionality of a tablet formulation of the sphingosine 1-phosphate-1 receptor modulator VTX002 (formerly OPL-002)	19
Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn’s Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018	18
Navigating Postoperative Management in Crohn’s Disease: Insights from the PORCSE Study	18
Decreased Levels of Atmospheric Pollution and Reduced Prevalence of Inflammatory Bowel Diseases in Europe	18
Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease	18
P623 The effectiveness and tolerability of Crohn’s disease exclusion diet in adult Crohn’s disease patients: a retrospective study	18
Clostridium perfringens: A Potential Pathobiont in Inflammatory Bowel Disease	18
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease	18
Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs	18
P551 Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn’s disease: application and prospective validation.	17
Disruption of Epithelial Barrier Integrity via Altered GILZ/c-Rel/RACK1 Signaling in Inflammatory Bowel Disease	17
DOP74 Comparative effectiveness of vedolizumab and ustekinumab in Crohn’s Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResource	17
Alteration in Urease-producing Bacteria in the Gut Microbiomes of Patients with Inflammatory Bowel Diseases	17
OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis	17
P113 Automatic detection of colonic ulcers and erosions in colon capsule endoscopy images using a convolutional neural network	17
P720 Exit interviews exploring Crohn’s disease patients’ experience of changes in their bowel urgency during the mirikizumab Phase 3 clinical trial in adult patients with moderate to severe Crohn dise	17
IBD Risk—It Is All in the Family!	17
P406 Disease clearance in patients with ulcerative colitis treated with aminosalicylates	17
P346 Assessing Brain Morphology in Functional Gastrointestinal and Inflammatory Bowel Disorders Using Functional Magnetic Resonance Imaging (fMRI)	17
Risk Prediction for Complications in Inflammatory Bowel Disease Surgery: External Validation of the American College of Surgeons’ National Surgical Quality Improvement Program Surgical Risk Calculator	17
Colectomy Rates did not Decrease in Paediatric- and Adult-Onset Ulcerative Colitis During the Biologics Era: A Nationwide Study From the epi-IIRN	17
P031 Class A1 scavenger receptor mediates macrophage polarization and apoptotic progression in a murine dextran sulfate sodium-induced colitis	17
P1137 Long-term trend of cumulative incidence of venous thromboembolism in Korean patients with inflammatory bowel disease: A nationwide population-based cohort study	16
P1218 Non-invasive point-of-care stool sample for detection of Cytomegalovirus infection in patients with Active or Refractory Ulcerative Colitis using multiplex polymerase chain reaction (mPCR): a pi	16
DOP41 Mucosal single-cell profiling of Crohn's-like disease of the pouch reveal unique pathogenesis and therapeutic targets	16
Serum Metabolites Relate to Mucosal and Transmural Inflammation in Paediatric Crohn Disease	16
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies	16
P738 Response to etrasimod treatment in ulcerative colitis is associated with a reduction of circulating B and pro-inflammatory T cells: a single-cell-based post-hoc sub-analysis of the ELEVATE UC 52	16
DOP03 Unfermented β-fructan fibres can induce gut inflammation and tumorigenesis in select Inflammatory Bowel Disease patients mediated by gut microbiota	16

P649 Long-term follow-up of the PROTDILAT study; LONG-PROTDILAT Prospective multicenter randomized comparative study of endoscopic treatment of strictures in Crohn's disease (CD): self-expandable meta	16
P084 Natural extracts and omega-3 derived molecule: role in resolution of intestinal inflammation	16
P1215 Blastocystis is very rare in faeces of children with Crohn’s disease: quantity, subtyping and association with the faecal bacteriome	16
N26 Disease outcomes and patient’s perspectives after switching biologics from intravenous to subcutaneous administration. A real-world experience in a tertiary IBD-unit	16
P1237 Development of an algorithm to identify the best donor-recipient match for FMT in IBD patients based on immune system/microbiota interactions	16
Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis	16
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients	16
P336 Exploring Extracellular Matrix Markers in Ulcerative Colitis: Degradation and Formation Insights	16
P623 Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s disease	16
P235 Correlation of mental and psychological status to disease activity in patients with Inflammatory Bowel Disease using The Symptom Checklist -90- Revised Questionnaire (SCL90R)	16
P526 Handsewn versus Stapled Ileocolic Anastomosis for Crohn's: Comparable Outcomes Despite More Severe Disease Profile in the Handsewn Group	16
P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study	16
DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort	16
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn’s Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled Trial	16
DOP03 Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey on processes and outcomes	16
DOP07 Targeting the canonical WNT signalling pathway as a potential novel therapy in Crohn′s associated fibrosis	15
P077 Different granulocyte subsets are involved in the pathogenesis in Crohn’s disease fistula	15
P963 The comparative effectiveness and safety of different biologics in young (<60 years) versus elderly (≥60 years) patients with IBD: results from a real-world experience at a Belgian tertiar	15
P743 Relative association of bowel urgency improvement versus remission of stool frequency and rectal bleeding with Patient Global Rating of Severity or Change scores in moderately-to-severely active	15
P607 HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease	15
P421 Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort study	15
DOP15 Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn’s disease: a multicentre prospective study	15
OP28 Children and young adults with inflammatory bowel disease have an increased incidence and risk of developing mental health conditions: a UK population-based cohort study	15
P940 A glance into paediatric Inflammatory Bowel Disease in Australasia – Crohn’s Colitis Cure (CCC) data insights program	15
P900 A PROOF-OF-CONCEPT, PLACEBO-RANDOMIZED CONTROLLED TRIAL TARGETING ADHERENT AND INVASIVE ESCHERICHIA COLI (AIEC) WITH ANTIBIOTICS IN CROHN’S DISEASE: the TEOREM TRIAL	15
P592 Higher predictive power of epigenetic signatures for response to vedolizumab and ustekinumab in anti-TNF naïve patients with active Crohn’s disease	15
P1075 Outcomes in patients stopping biologic during the first trimester of pregnancy : a retrospective monocentric study	15
P022 A correlation of serum Fibroblast Growth Factor 21 level with inflammatory markers and indicators of nutritional status in patients with Inflammatory Bowel Disease	15
P307 High frequency of Deep Infiltrating Endometriosis in patients with Inflammatory Bowel Disease: a nested case-control study	15
P128 Salt-Inducible Kinase 2 is a promising therapeutic target in patients with ulcerative colitis	15
DOP05 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease	15
P393 Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis	15
P505 Early therapeutic drug monitoring after induction therapy with infliximab: correlation with intestinal ultrasound	15
DOP68 Autophagy induction in the intestinal epithelium protects against inflammation-induced barrier loss in vivo.	14
P103 Colitis-associated faecal miRNAs are mediators of host-microbiota interactions and key regulators of intestinal permeability and inflammation	14
P094 Impacts of 5-aminosalicylic acid on the intestinal microbiota leading to the anti-inflammatory effect	14
P507 United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey	14
DOP55 The increasing burden of direct and indirect costs of IBD	14
P041 The upregulation of tissue factor in colonic mesenchymal cells in active ulcerative colitis is associated with severe and resistant to treatment disease, but tofacitinib has not effect on it	14
P569 Can thiopurines prevent crohn’s disease endoscopic postoperative recurrence in at risk patients?	14
P830 Significant racial and ethnic disparities exist in health-care utilization in inflammatory bowel disease: a systematic review and meta-analysis	14
P810 Association between Ustekinumab Trough Levels, Serum IL-22 and Oncostatin M Levels with Clinical and Biochemical Outcomes in Patients With Crohn’s Disease	14
P329 Stool multiplex molecular PCR assay in comparison to conventional stool tests for detecting gastrointestinal infections as cause of flares in Inflammatory Bowel Disease	14
P152 The prevalence of Thiopurine-methyltransferase and NUTD15 in patient with ulcerative colitis: a hospital-based study in central Taiwan	14
P030 Assessing dietetic interventions in inflammatory bowel disease patients	14
P524 Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC study	14
P349 Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Descriptive Comparison of Experiences of Bowel Urgency among Patients with Ulcerative Colitis in Canada, Europe, and the US	13
ECCO Grant Dissecting the intestinal mucosa-associated HUMoral immune response in ileal Crohn’s Disease: the HUM-CD study	13
P757 Visceral adiposity and not subcutaneous adiposity or body mass index is more strongly associated with relapse in inflammatory bowel disease	13
DOP46 Sustainability rate of immunomodulators monotherapy in patients with Crohn’s Diseases: A population-based analysis from the epi-IIRN cohort	13
P100 Salivary exosomes aggravate colitis via oral-gut axis	13
P1020 Developing and Validating a Clinical Prediction Model Using Biomarkers to Assess Clinical Response and Severity of Crohn's Disease 12 Weeks After Initiation of Biological Therapy	13
N31 Nothing about us, without us: Developing a reliable IBD information source on sexual well-being by patients and for patients	13
P263 Influence of Crohn′s Disease phenotype in the retention rate of ustekinumab treatment: SUSTAIN Study	13
P585 Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure	13
P119 Single-cell RNA sequencing in Inflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis: a distinct form of colitis	13
P518 Partial enteral nutrition use for Crohn’s disease management: a systematic review	13
P161 The use of Novel Natural Treatments for Inflammatory Bowel Diseases	12
P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison	12
P189 Lifestyle and psychosocial factors in IBD; prevalence and patients’ perspective	12
P491 Infectious risk of vedolizumab compared with other biological agents in the treatment of Inflammatory Bowel Disease	12
P045 Oncostatin M induces strong fibrotic and chemokine responses from primary colonic subepithelial myofibroblasts	12
P071 Crohn’s Disease is associated with elevated levels of the pro-inflammatory CXCR3 ligands (CXCL9, 10 and 11) with an associated reduction in Paneth cell derived antimicrobial peptides in ex-vivo i	12
P388 Eliakim score performance among patients with active Crohn’s disease	12
P811 Age as a Predictor of Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Retrospective Study	12
DOP27 Systemic antibody responses against gut microbiota flagellins implicate shared and divergent immune reactivity in Crohn's Disease and chronic fatigue syndrome	12
DOP41 Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study	12
DOP65 Dietary therapy with the Crohn’s Disease exclusion diet induces sustained clinical and endoscopic remission in adults with Mild to Moderate Crohn’s Disease: Results from the CDED-AD trial	12
P063 The immunological landscape of intestinal fibrosis in Crohn’s Disease	12
P512 Early proactive therapeutic drug monitoring with ustekinumab therapy in paediatric Crohn's Disease	12
P012 Intestinal epithelial cells as targets of thiopurines in Inflammatory Bowel Disease paediatric patients-derived organoids	12
P319 Genetic polymorphism of lactose intolerance in patients with Inflammatory Bowel Disease	12
P325 Proton pump inhibitors are associated with a disabling course of Crohn’s disease	12
P657 Persistence in smoking cessation in inflammatory bowel disease (IBD)	12
P0356 A case of pulmonary nodules in Ulcerative Colitis and primary sclerosing cholangitis: is it drug or disease?	12
P879 Clinical significance of plasma interleukin-22 as a biomarker of inflammation in patients with Crohn’s disease and ulcerative colitis	12
P687 Durability of recaptured response to ozanimod during the True North open-label extension	12
P1300 HLA-C*06 Genotype and Ustekinumab Therapy Persistence in Inflammatory Bowel Disease	11
P0965 Sequencing Therapy for Optimal Response in Mirikizumab (STORM) Study	11
OP40 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn’s disease: result	11
P0447 Accurate, rapid and economical diagnosis of chronic enteropathy associated with SLCO2A1 gene and the analysis of its clinical pathological features	11
P1199 Early life exposures predict childhood-onset IBD in a population-based cohort	11
P1144 Effect of baseline disease severity on achieving efficacy endpoints in patients with Ulcerative Colitis treated with filgotinib	11
DOP008 High clinical and endoscopic remission rate with Vedolizumab in early CD patients: the 2nd interim analysis from a prospective multicenter interventional Study (EARLY CD)	11
P0954 Food-related quality of life and dietary choices are associated with disease activity in patients with inflammatory bowel disease	11
P213 Having Inflammatory Bowel Disease Negatively Impacts Household and Family Life	11
DOP104 International differences in pre-operative characteristics and postoperative management in patients with Crohn’s disease following ileocolic resection: a report from the IMPACT consortium	11
P1198 Statin Use for Primary Prevention of Cardiovascular Disease and its Association with Risk of Incident Inflammatory Bowel Disease: A Population-Based Cohort Study	11
P1123 Baseline characteristics and nutrition in patients with moderately to severely active Inflammatory Bowel Disease: Results from the phase 3 UNITI Jr and UNIFI Jr trials	11
P1133 Safety and effectiveness of indigo naturalis for induction of remission in children with mild to moderate ulcerative colitis: a prospective open-label trial	11
P0985 Real-world experience of subcutaneous infliximab use in children with inflammatory bowel disease (IBD) at a tertiary paediatric centre	11
P164 Celiac Disease among a large cohort of inflammatory bowel disease patients: epidemiology and outcome implications	11
P125 MIG (CXCL9) and IL22 are key biomarkers that discriminates between paediatric IBD patients and non-IBD patients in a novel biomarker model	11
P0211 Characterization of drug-specific CD4+ T cells in patients with inflammatory bowel diseases	11
DOP063 Hospitalised severe ulcerative colitis patients treated with rescue infliximab risk treatment failure due to underexposure caused by high drug clearance	11